Loading stock data…
$0.96-0.11 (-10.27%)
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
Marker Therapeutics, Inc. in the Healthcare sector is trading at $0.96 with a market capitalization of $21M. Wall Street consensus targets $7.87 (3 analysts), implying a +719.4% move over the next 12 months. The stock is currently near its 52-week low of $0.84, remaining 30.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.94M↑ | -$3.32M↓ | -$1.88M↑ | -$2.14M↑ | -$4.26M |
| Net Income | -$1.83M↑ | -$3.18M↓ | -$1.70M↑ | -$2.00M↑ | -$4.02M |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antige...